FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897061362> ?p ?o ?g. }

• W2897061362 endingPage "42" @default.
• W2897061362 startingPage "32" @default.
• W2897061362 abstract "BackgroundThe choice of a primary treatment for ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) depends on the extent of tumor spread. However, radiotherapy is commonly used as a first-line therapy despite ophthalmic complications, because most OAMLs are in a limited stage of progression. However, the initial therapeutic modality, including chemotherapy and treatment of the advanced stage, has not been fully established for OAML. Therefore, we evaluated the optimal therapeutic options and survival outcome-related parameters for patients with primary OAML.MethodsWe evaluated 208 consecutive patients with primary OAML who were diagnosed at the Catholic University Lymphoma Group between January 2004 and April 2015.FindingsDuring a median follow-up of 70.0 months (range, 3.2–182.0 months) in 208 patients with primary OAML, most patients were female and the median age was 46 years old. Overall survival (OS) and progression-free survival (PFS) at 13 years were excellent (92.7% and 69.7%, respectively). Of the 117 patients who received the first-line radiotherapy, 92% achieved complete remission (CR), usually by being treated with less than 30 Gy. Radiation-related ophthalmic complications including dry eye syndrome (59%) and cataract (22%) caused a decline in the quality of life (QoL). Chemotherapy alone was used to treat 86 OAML patients, with 84.9% achieving CR and 12.8% achieving partial remission with tolerable toxicities. There were no differences in survival outcomes between patients treated with radiotherapy versus those treated with rituximab-containing chemotherapy, although the latter group had more advanced stages of OAML (OS, p = 0.057; PFS, p = 0.075).InterpretationOAML patients were predominantly female and relatively young, and radiotherapy as a primary therapeutic option was more likely to lead to radiation-related complications, resulting in lower QoL. On the other hand, frontline chemotherapy showed consistent therapeutic outcomes with tolerable toxicities compared to radiotherapy, and there were no long-term or delayed adverse events. Therefore, when considering therapeutic efficacy and therapy-related QoL, chemotherapy is recommended for younger patients, and radiotherapy is recommended for older and chemotherapy-ineligible patients.FundingA National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. NRF-2016R1A2B4007282)." @default.
• W2897061362 created "2018-10-26" @default.
• W2897061362 creator A5001142175 @default.
• W2897061362 creator A5013472021 @default.
• W2897061362 creator A5021692797 @default.
• W2897061362 creator A5021863765 @default.
• W2897061362 creator A5022841529 @default.
• W2897061362 creator A5059291757 @default.
• W2897061362 creator A5084199210 @default.
• W2897061362 creator A5086008585 @default.
• W2897061362 date "2018-10-01" @default.
• W2897061362 modified "2023-09-27" @default.
• W2897061362 title "Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma" @default.
• W2897061362 cites W1491196545 @default.
• W2897061362 cites W1561852313 @default.
• W2897061362 cites W1965794156 @default.
• W2897061362 cites W1967724532 @default.
• W2897061362 cites W1981908549 @default.
• W2897061362 cites W1982738765 @default.
• W2897061362 cites W1984832320 @default.
• W2897061362 cites W1988938043 @default.
• W2897061362 cites W1992530733 @default.
• W2897061362 cites W1994197048 @default.
• W2897061362 cites W1994474744 @default.
• W2897061362 cites W1998276281 @default.
• W2897061362 cites W1998829583 @default.
• W2897061362 cites W2000102591 @default.
• W2897061362 cites W2009540999 @default.
• W2897061362 cites W2016193783 @default.
• W2897061362 cites W2028277032 @default.
• W2897061362 cites W2028671392 @default.
• W2897061362 cites W2028762943 @default.
• W2897061362 cites W2031328526 @default.
• W2897061362 cites W2031836488 @default.
• W2897061362 cites W2050419268 @default.
• W2897061362 cites W2050941456 @default.
• W2897061362 cites W2051334720 @default.
• W2897061362 cites W2052861764 @default.
• W2897061362 cites W2061007663 @default.
• W2897061362 cites W2070720686 @default.
• W2897061362 cites W2071167848 @default.
• W2897061362 cites W2083415414 @default.
• W2897061362 cites W2084122907 @default.
• W2897061362 cites W2087862155 @default.
• W2897061362 cites W2087885595 @default.
• W2897061362 cites W2092939241 @default.
• W2897061362 cites W2095035604 @default.
• W2897061362 cites W2099747441 @default.
• W2897061362 cites W2100205544 @default.
• W2897061362 cites W2106800025 @default.
• W2897061362 cites W2112764164 @default.
• W2897061362 cites W2123369918 @default.
• W2897061362 cites W2124845889 @default.
• W2897061362 cites W2133201432 @default.
• W2897061362 cites W2136596222 @default.
• W2897061362 cites W2139639997 @default.
• W2897061362 cites W2156013764 @default.
• W2897061362 cites W2159366906 @default.
• W2897061362 cites W2159872381 @default.
• W2897061362 cites W2165623211 @default.
• W2897061362 cites W2171625299 @default.
• W2897061362 cites W2273517499 @default.
• W2897061362 cites W2414079186 @default.
• W2897061362 cites W2518412116 @default.
• W2897061362 cites W2540225427 @default.
• W2897061362 cites W2740988213 @default.
• W2897061362 cites W4237054892 @default.
• W2897061362 cites W4239464349 @default.
• W2897061362 cites W4240920161 @default.
• W2897061362 cites W4247381534 @default.
• W2897061362 cites W4380147387 @default.
• W2897061362 doi "https://doi.org/10.1016/j.eclinm.2018.10.001" @default.
• W2897061362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6537565" @default.
• W2897061362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31193655" @default.
• W2897061362 hasPublicationYear "2018" @default.
• W2897061362 type Work @default.
• W2897061362 sameAs 2897061362 @default.
• W2897061362 citedByCount "9" @default.
• W2897061362 countsByYear W28970613622020 @default.
• W2897061362 countsByYear W28970613622022 @default.
• W2897061362 countsByYear W28970613622023 @default.
• W2897061362 crossrefType "journal-article" @default.
• W2897061362 hasAuthorship W2897061362A5001142175 @default.
• W2897061362 hasAuthorship W2897061362A5013472021 @default.
• W2897061362 hasAuthorship W2897061362A5021692797 @default.
• W2897061362 hasAuthorship W2897061362A5021863765 @default.
• W2897061362 hasAuthorship W2897061362A5022841529 @default.
• W2897061362 hasAuthorship W2897061362A5059291757 @default.
• W2897061362 hasAuthorship W2897061362A5084199210 @default.
• W2897061362 hasAuthorship W2897061362A5086008585 @default.
• W2897061362 hasBestOaLocation W28970613621 @default.
• W2897061362 hasConcept C126322002 @default.
• W2897061362 hasConcept C141071460 @default.
• W2897061362 hasConcept C143998085 @default.
• W2897061362 hasConcept C146357865 @default.
• W2897061362 hasConcept C151730666 @default.
• W2897061362 hasConcept C2776694085 @default.
• W2897061362 hasConcept C2779338263 @default.

• next